Clindamycin is an orally active, broad-spectrum bacteriostatic lincosamide antibiotic. It inhibits bacterial protein synthesis and can suppress the expression of virulence factors in *Staphylococcus aureus* at sub-inhibitory concentrations (sub-MICs). Resistance to Clindamycin occurs due to enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin also reduces the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1), or alpha-haemolysin (Hla), and can be used in malaria research.
- Orally active
- Broad-spectrum bacteriostatic lincosamide antibiotic
- Inhibits bacterial protein synthesis
- Suppresses virulence factor expression in *Staphylococcus aureus*
- Decreases production of PVL, TSST-1, or Hla
- Can be used for malaria research